Compare NXJ & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXJ | KROS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 584.9M |
| IPO Year | N/A | 2020 |
| Metric | NXJ | KROS |
|---|---|---|
| Price | $12.47 | $13.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 112.1K | ★ 277.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | N/A | ★ 3.85 |
| EPS | N/A | ★ 2.68 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6,898.87 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.01 | $9.12 |
| 52 Week High | $12.90 | $22.55 |
| Indicator | NXJ | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 23.64 |
| Support Level | $11.24 | $13.42 |
| Resistance Level | $12.76 | $15.02 |
| Average True Range (ATR) | 0.09 | 0.60 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 17.21 | 15.85 |
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.